Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, S Kang P, Shankaran V et al..  2017.  IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.. J Clin Invest. 127(8):2930-2940.

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L et al..  2017.  An immunogenic personal neoantigen vaccine for patients with melanoma.. Nature. 547(7662):217-221.

Price EW, Carnazza KE, Carlin SD, Cho A, Edwards KJ, Sevak KK, Glaser JM, de Stanchina E, Janjigian YY, Lewis JS.  2017.  Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection.. J Nucl Med. 58(9):1386-1394.

Sibaud V, Niec RE, Schindler K, Busam KJ, Roché H, Modi S, Delord JPierre, Lacouture ME.  2014.  Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series.. Breast Cancer Res Treat. 146(2):451-6.

Wang CQF, Suárez-Fariñas M, Nograles KE, Mimoso CA, Shrom D, Dow ER, Heffernan MP, Hoffman RW, Krueger JG.  2014.  IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood.. J Invest Dermatol. 134(12):2990-2993.

Fan X, Upadhyaya B, Wu L, Koh C, Santín-Durán M, Pittaluga S, Uzel G, Kleiner D, Williams E, Ma CA et al..  2012.  CD40 agonist antibody mediated improvement of chronic Cryptosporidium infection in patients with X-linked hyper IgM syndrome.. Clin Immunol. 143(2):152-61.